Molecular Neurodegeneration

Article	Citations
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	332
Regulation of the hippocampal translatome by Apoer2-ICD release	205
Tau interactome and RNA binding proteins in neurodegenerative diseases	202
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	182
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	182
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	180
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	180
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	166
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	157
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	154
Neuroprotection by WldS depends on retinal ganglion cell type and age in glaucoma	151
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	147
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	139
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	137
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	136
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	133
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	121
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	116
Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer’s disease brains	114
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	113
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	108
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	108
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	106
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	94
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	90

Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	88
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	87
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	85
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	84
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	81
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	80
Combination therapy using GDNF and cell transplant in Parkinson’s disease	79
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	68
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	68
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	66
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	63
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	63
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	63
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	63
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	63
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	62
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	62
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	60
Using mass spectrometry to validate mouse models of tauopathy	60
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration	59
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	58
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	56
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	55
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	54
The endotoxin hypothesis of Alzheimer’s disease	54
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	53
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	51
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	51
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	51
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	51
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	51
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	50
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	49
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	49
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	48
SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease	47
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’	47
Mechanisms of astrocyte aging in reactivity and disease	47
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	46
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	45
VCP suppresses proteopathic seeding in neurons	45
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	44
Sex specific molecular networks and key drivers of Alzheimer’s disease	43
Wild-type FUS corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation	42
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans	41
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	39
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	39
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	38
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	38
SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis	38

Neuropathology and molecular diagnosis of Synucleinopathies	38
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	37
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	37
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	36
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	36
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	36
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	35
MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous Toll-like receptor 7/8 ligands that contribute to neurodegeneration	34
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	34
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	34
Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy	34
The role of inflammasomes in vascular cognitive impairment	33
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	33
CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice	33
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	33
Blood platelet factor 4: the elixir of brain rejuvenation	32
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	32
TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis	31
Targeted long-read sequencing to quantify methylation of the C9orf72 repeat expansion	31
Seeding activity of skin misfolded tau as a biomarker for tauopathies	31
Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species	31
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease	31
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	30
BACE1 regulates expression of Clusterin in astrocytes for enhancing clearance of β-amyloid peptides	30
Elevated nuclear TDP-43 induces constitutive exon skipping	30
Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease	30
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	30
Microglial ferroptotic stress causes non-cell autonomous neuronal death	30
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential	30
Correction: Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	29
Early transcriptional and cellular abnormalities in choroid plexus of a mouse model of Alzheimer’s disease	29
Mouse models of Anti-Aβ immunotherapies	28
HDGFL2 cryptic protein: a portal to detection and diagnosis in neurodegenerative disease	28
cGAS-STING triggers inflammaging-associated neurodegeneration	28
Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity	27
Gut microbiota-host lipid crosstalk in Alzheimer’s disease: implications for disease progression and therapeutics	27
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	27
ACSS2-dependent histone acetylation improves cognition in mouse model of Alzheimer’s disease	27
Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer’s disease	27
The integrated stress response in neurodegenerative diseases	27
TREM2 and microglia exosomes: a potential highway for pathological tau	26
An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders	26
Loss of MEF2C function by enhancer mutation leads to neuronal mitochondria dysfunction and motor deficits in mice	26
Astrocytes of the optic nerve exhibit a region-specific and temporally distinct response to elevated intraocular pressure	26
Immune cell metabolic dysfunction in Parkinson’s disease	25
Mitochondrial CISD1/Cisd accumulation blocks mitophagy and genetic or pharmacological inhibition rescues neurodegenerative phenotypes in Pink1/parkin models	25
Pharmacological rescue of cognitive function in a mouse model of chemobrain	25
Aging-associated sensory decline and Alzheimer’s disease	25
A novel AAV Vector for gene therapy of RPE-related retinal degenerative diseases via intravitreal delivery	25
A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques	25
Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	25
Microglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis	24
TDP-43 pathology is associated with increased tau burdens and seeding	24
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy	24
Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells	24
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium	24
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease	24
Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells	23
Knock-in models related to Alzheimer’s disease: synaptic transmission, plaques and the role of microglia	23
Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD	23
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	23
Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease	23
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	23
Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains	22
TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains	22
hiPSC-based models to decipher the contribution of human astrocytes to Alzheimer’s disease and potential therapeutics	22
Are oligodendrocytes the missing link in Alzheimer’s disease and related dementia research?	22
Correction: Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	22
Inactivation of NLRP3 inflammasome by dephosphorylation at Serine 658 alleviates glial inflammation in the mouse model of Parkinson’s disease	21
Single-domain antibody-based protein degrader for synucleinopathies	21
Fate-mapping and functional dissection reveal perilous influence of type I interferon signaling in mouse brain aging	21
The concept of resilience to Alzheimer’s Disease: current definitions and cellular and molecular mechanisms	21
The neuroimmune nexus: unraveling the role of the mtDNA-cGAS-STING signal pathway in Alzheimer’s disease	21
Does proteopathic tau propagate trans-synaptically in the brain?	19
18F-MK-6240 tau PET in patients at-risk for chronic traumatic encephalopathy	19
Functional microRNA targetome undergoes degeneration-induced shift in the retina	19
Lewy body diseases and the gut	19
Tau protein profiling in tauopathies: a human brain study	19
When the infectious environment meets the AD brain	18
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia	18

Disparate and shared transcriptomic signatures associated with cortical atrophy in genetic behavioral variant frontotemporal degeneration	18
Genome-wide analyses identify NEAT1 as genetic modifier of age at onset of amyotrophic lateral sclerosis	18
Tauopathies: new perspectives and challenges	18
Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease	18
Translation dysregulation in neurodegenerative diseases: a focus on ALS	18
Alzheimer’s genes in microglia: a risk worth investigating	18
Cellular and molecular mechanisms of pathological tau phosphorylation in traumatic brain injury: implications for chronic traumatic encephalopathy	18
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology	17
To the editor: Response to post-infection cognitive impairments in a cohort of elderly patients with COVID-19, by Wang, Y.J. et al. (2021)	17
Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease	17
Crosstalk of organelles in Parkinson’s disease – MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes	17
Insights from new in vivo models of TREM2 variants	17
Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology	17
Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer’s disease	17
Alzheimer’s disease associated isoforms of human CD33 distinctively modulate microglial cell responses in 5XFAD mice	17
Simple model systems reveal conserved mechanisms of Alzheimer’s disease and related tauopathies	16
Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	16
Single-cell microglial transcriptomics during demyelination defines a microglial state required for lytic carcass clearance	16
Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers	16
Urolithin A promotes p62-dependent lysophagy to prevent acute retinal neurodegeneration	16
CD8+ T cells in neurodegeneration: friend or foe?	16
Nuclear speckle specific hnRNP D-like prevents age- and AD-related cognitive decline by modulating RNA splicing	16
Updates on mouse models of Alzheimer’s disease	15
The Alzheimer’s disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130	15
Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer’s disease	15
Genetic context modulates aging and degeneration in the murine retina	14
Altered plasma protein profiles in genetic FTD – a GENFI study	14
Author response to “post-infection cognitive impairments in a cohort of elderly patients with COVID-19”	14
Regulatory T cells limit age-associated retinal inflammation and neurodegeneration	13
Mitovesicles secreted into the extracellular space of brains with mitochondrial dysfunction impair synaptic plasticity	13
17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are associated with LRRC37A/2 expression in astrocytes	13
Research models to study lewy body dementia	13
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events	13
Translational molecular imaging and drug development in Parkinson’s disease	12
The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD	12
RNA-Targeting CRISPR/CasRx system relieves disease symptoms in Huntington’s disease models	12
TREM2 and sTREM2 in Alzheimer’s disease: from mechanisms to therapies	12
The informed road map to prevention of Alzheimer Disease: A call to arms	12
Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer’s disease	12
Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come	11
Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases	11
A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy	11
A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer’s disease patients from controls	11
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	11
Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications	11
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	11